The estimated Net Worth of Neil Stahl is at least $92.5 Millón dollars as of 8 August 2024. Neil Stahl owns over 5,197 units of Regeneron Pharmaceuticals stock worth over $58,212,809 and over the last 22 years he sold REGN stock worth over $25,191,644. In addition, he makes $9,137,220 as Executive Vice President - Research and Development at Regeneron Pharmaceuticals.
Neil has made over 47 trades of the Regeneron Pharmaceuticals stock since 2004, according to the Form 4 filled with the SEC. Most recently he sold 5,197 units of REGN stock worth $5,636,354 on 8 August 2024.
The largest trade he's ever made was exercising 116,666 units of Regeneron Pharmaceuticals stock on 13 February 2012 worth over $1,406,992. On average, Neil trades about 21,542 units every 100 days since 2003. As of 8 August 2024 he still owns at least 50,999 units of Regeneron Pharmaceuticals stock.
You can see the complete history of Neil Stahl stock trades at the bottom of the page.
Dr. Neil Stahl Ph.D. serves as Executive Vice President - Research and Development of the Company since January 2015. He previously served as Senior Vice President, Research and Development Sciences from January 2007 to December 2014, as Senior Vice President, Preclinical Development and Biomolecular Sciences from December 2000 to December 2007, and as Vice President, Preclinical Development and Biomolecular Sciences from January 2000 to December 2000. He joined the Company in 1991. Before becoming Vice President, Biomolecular Sciences in 1997, Dr. Stahl was Director, Cytokines and Signal Transduction. Dr. Stahl received his Ph.D. in Biochemistry from Brandeis University.
As the Executive Vice President - Research and Development of Regeneron Pharmaceuticals, the total compensation of Neil Stahl at Regeneron Pharmaceuticals is $9,137,220. There are 5 executives at Regeneron Pharmaceuticals getting paid more, with P. Roy Vagelos having the highest compensation of $22,304,300.
Neil Stahl is 63, he's been the Executive Vice President - Research and Development of Regeneron Pharmaceuticals since 2014. There are 7 older and 16 younger executives at Regeneron Pharmaceuticals. The oldest executive at Regeneron Pharmaceuticals, Inc. is P. Roy Vagelos, 90, who is the Chairman of the Board, Director.
Over the last 22 years, insiders at Regeneron Pharmaceuticals have traded over $13,084,686,326 worth of Regeneron Pharmaceuticals stock and bought 8,562,481 units worth $2,539,854,760 . The most active insiders traders include Sanofi, Pharma Ag Novartis y Leonard S Schleifer. On average, Regeneron Pharmaceuticals executives and independent directors trade stock every 8 days with the average trade being worth of $47,694,347. The most recent stock trade was executed by Marion Mc Court on 3 September 2024, trading 1,000 units of REGN stock currently worth $381,400.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
Regeneron Pharmaceuticals executives and other stock owners filed with the SEC include: